Lopo

Losartan Potassium

Composition:

• Lopo 25 mg Tablet: Each film-coated tablet contains Losartan Potassium USP 25 mg.
• Lopo 50 mg Tablet: Each film-coated tablet contains Losartan Potassium USP 50 mg.

Description:

Losartan Potassium USP (Lopo tablet) is an angiotensin II receptor (type AT1) antagonist, which is the first of a new class of antihypertensive drugs.

Indication:

• Lopo tablet is indicated for the treatment of hypertension. It may also be alone or in combination with other antihypertensive agents.

Mechanism of action:

Angiotensin II (formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme), is a potent vasoconstrictor, the primary vasoactive hormone of the renin- Angiotensin system, and an important component in the pathophysiology of hypertension. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of Angiotensin II by selectively blocking the binding of Angiotensin II to the AT1, receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). Both losartan and its principal active metabolites do not exhibit any partial agonist activity at the AT1 receptor and have a much greater affinity for the AT1 receptor than for the AT2 receptor. Neither losartan nor its active metabolite inhibits ACE, nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

Pharmacokinetics:

Following oral administration, losartan is well absorbed, and undergoes presystemic metabolism, forming an active metabolite and other inactive metabolites. The bioavailability of Lopo tablets is approximately 33%. Mean peak concentrations of losartan and its active metabolites are reached in 1 hour and in 3 - 4 hours respectively. Both losartan and its principal active metabolites are >98% bound to plasma proteins primarily albumin. The volume of distribution of losartan is relatively low. Following oral administration, the pharmacokinetics of losartan and its principal active metabolites are linear with doses up to 200 mg. Losartan is extensively metabolized in the liver. Approximately 35% of an oral dose is excreted in the urine as unchanged compounds and metabolites.

Dosage and Administration:

The usual starting dose of Lopo tablet is 50 mg once daily, with 25 mg used in patients with possible depletion of intravascular volume and patients with a history of hepatic impairment. Lopo tablets can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. The maximum antihypertensive effect is attained 3 - 6 weeks after initiation of therapy. No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients for dialysis. Lopo tablets may be administered with other antihypertensive agents. It may be administered with or without food.

Precautions:

In patients who are intravascularly volume depleted (e.g. those treated with high-dose diuretics), symptomatic hypotension may occur. These conditions should be corrected prior to administration of the Lopo tablet or a lower starting dose should be used. A lower dose should be considered for patients with a history of hepatic impairment.

Side effects:

Side effects have usually been mild and transient in nature and have not required discontinuation of therapy. Angioedema has been reported rarely in patients treated with Lopo tablets. Other side effects include diarrhea, liver function abnormalities, myalgia, migraine, urticaria, and pruritus.

Drug Interaction:

As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to an increase in serum potassium.

Use in pregnancy and Lactation:

Lopo tablets should not be used in pregnancy. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Commercial Pack:

• Lopo 25 mg Tablet: Each Box contains 3X10 tablets in a blister pack.
• Lopo 50 mg Tablet: Each Box contains 3X10 tablets in the blister pack.

Biopharma Ltd. Produces LOPO 50 MG TABLET it is a trusted product for alleviating various discomforts, and it's commonly found in pharmacies and stores.